Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe

Updated on: January 08,2024 10

Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe

Updated on:January 08,2024 10

Plugging immune cell leakage from tumors could improve skin cancer treatment

byNYU Langone HealthMelanoma. Credit: Wikimedia Commons/National Cancer InstituteThe number of specialized immune cells available for fighting skin cancer doubled when a new treatment blocked th

Updated on: December 20,2023 12

Plugging immune cell leakage from tumors could improve skin cancer treatment

byNYU Langone HealthMelanoma. Credit: Wikimedia Commons/National Cancer InstituteThe number of specialized immune cells available for fighting skin cancer doubled when a new treatment blocked th

Updated on:December 20,2023 12

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on: October 15,2023 284

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on:October 15,2023 284

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on: October 17,2023 240

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on:October 17,2023 240

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on: December 20,2023 19

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on:December 20,2023 19

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on: November 02,2023 10

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on:November 02,2023 10

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on: December 26,2023 8

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on:December 26,2023 8

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on: December 19,2023 12

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on:December 19,2023 12

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi

Updated on: December 21,2023 15

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi

Updated on:December 21,2023 15

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023 205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023 205

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023 156

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023 156

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA

Updated on: December 21,2023 10

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA

Updated on:December 21,2023 10